These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28838265)

  • 21. Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study.
    Tu Y; Tian Y; Fang Z; Ruan Q; Tang H; Zhang X; Wu Y; Ding Y; Cui S
    Int J Hyperthermia; 2016 Sep; 32(6):587-94. PubMed ID: 27362668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly: A Case-Controlled, Multicenter Study.
    Alyami M; Lundberg P; Kepenekian V; Goéré D; Bereder JM; Msika S; Lorimier G; Quenet F; Ferron G; Thibaudeau E; Abboud K; Lo Dico R; Delroeux D; Brigand C; Arvieux C; Marchal F; Tuech JJ; Guilloit JM; Guyon F; Peyrat P; Pezet D; Ortega-Deballon P; Zinzindohoue F; de Chaisemartin C; Kianmanesh R; Glehen O; Passot G;
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):737-745. PubMed ID: 27600619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
    Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
    Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chen CY; Chang HY; Lu CH; Chen MC; Huang TH; Lee LW; Liao YS; Chen VC; Huang WS; Ou YC; Lung FC; Wang TY
    Int J Hyperthermia; 2020; 37(1):1279-1286. PubMed ID: 33198563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Canda AE; Sokmen S; Terzi C; Arslan C; Oztop I; Karabulut B; Ozzeybek D; Sarioglu S; Fuzun M
    Ann Surg Oncol; 2013 Apr; 20(4):1082-7. PubMed ID: 23456387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated Maximum Core Body Temperature During Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) is Associated with Increased Postoperative Complications.
    Hendrix RJ; Kassira JP; Lambert LA
    Ann Surg Oncol; 2020 Jan; 27(1):232-239. PubMed ID: 31286314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Konstantinidis IT; Chouliaras K; Levine EA; Lee B; Votanopoulos KI
    Ann Surg Oncol; 2017 Dec; 24(13):3825-3830. PubMed ID: 29019118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
    Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
    Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
    Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V
    Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience.
    Navez J; Remue C; Leonard D; Bachmann R; Kartheuser A; Hubert C; Coubeau L; Komuta M; Van den Eynde M; Zech F; Jabbour N
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):666-673. PubMed ID: 27646023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kusamura S; Baratti D; Antonucci A; Younan R; Laterza B; Oliva GD; Gavazzi C; Deraco M
    Ann Surg Oncol; 2007 Dec; 14(12):3443-52. PubMed ID: 17909918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details.
    Topgül K; Çetinkaya MB; Çiğdem Arslan N; Gül MK; Çan M; Gürsel MF; Erdem D; Malazgirt Z
    Ulus Cerrahi Derg; 2015; 31(3):138-47. PubMed ID: 26504417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.